Skip to content

Milo Biotechnology’s FDA Orphan Drug Designation For Muscular Dystrophy

December 28, 2012

Milo Biotechnology’s experimental drug AAV1-FS344 receives FDA Orphan Drug Designation (ODD) on November 19, 2012, for the treatment of Duchenne and Becker Muscular Dystrophy (DMD & BMD, respectively). Orphan drug AAV1-FS344 is a “gene delivery therapy that produces Follistatin, a protein that increases muscle mass and strength”, in patients with both types of Muscular Dystrophy.

A Phase I clinical trial, funded by the Parent Project Muscular Dystrophy (PPMD) foundation, is underway for AAV1-FS344 in adults with BMD and inclusion body myositis, at the Nationwide Children’s Hospital in Columbus, Ohio.

References

Muscular Dystrophy Association’s (MDA) December 27, 2012 article titled, “MD Briefs: Gene Therapy, Exon Skipping, Stem Cells”

StreetInsider.com December 12, 2012 article/newswire titled, “Milo Biotechnology announces FDA Orphan Drug Designation for AAV1-FS344 for treatment of Duchenne and Becker Muscular Dystrophy”

Copyright © 2012-2013, Orphan Druganaut Blog. All rights reserved

Advertisements
Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: